However, clinical development of TGR5 agonists for the treatment of metabolic diseases has been hindered by side effects associated with systemic TGR5 agonism, including inhibition of gallbladder emptying (5, 22), which can lead to gallstone formation, and changes in heart rate and blood pressure (28, 29). Here, GPBAR1 is linked to gallstones.